Results 31 to 40 of about 145,187 (366)

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]

, 2020
In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco, Francis, Heather, Kennedy, Lindsey, Kundu, Debjyoti, Meadows, Vik   +4 more
core   +1 more source

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Pharmaceutical Research, 2022
Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage form.
Manojkumar Mahapatra, M. Karuppasamy, B. Sahoo   +2 more
semanticscholar   +1 more source

Сomparative Study of Progepar Efficacy in Patients with Non-Alcoholic Steatohepatitis

Gastroenterologìa, 2015
Non-alcoholic fatty liver disease is one of the most common pathologies of the liver in developed countries. On the average, its prevalence reaches 20 %.
V.G. Perederii, G.K. Syzenko
doaj   +1 more source

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis

JGH Open, 2022
Background Non‐alcoholic fatty liver (NAFL) can progress to the severe subtype non‐alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs.
Sina Ghandian, Rahul Thapa, Anurag Garikipati, Gina Barnes, Abigail Green‐Saxena, Jacob Calvert, Qingqing Mao, Ritankar Das   +7 more
doaj   +1 more source

Animal models of NASH: getting both pathology and metabolic context right [PDF]

, 2015
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease.
Larter, Claire Z., Yeh, Matthew M.
core   +1 more source

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis

Liver international (Print), 2021
Non‐alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end‐stage liver disease (ESLD). A large proportion of early‐stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive ...
J. Schattenberg, J. Lazarus, P. Newsome, L. Serfaty, A. Aghemo, S. Augustin, E. Tsochatzis, V. de Lédinghen, E. Bugianesi, M. Romero‐Gomez, H. Bantel, S. Ryder, J. Boursier, V. Leroy, J. Crespo, L. Castéra, L. Floros, V. Atella, J. Mestre-Ferrandiz, R. Elliott, A. Kautz, A. Morgan, S. Hartmanis, S. Vasudevan, L. Pezzullo, A. Trylesinski, S. Cure, V. Higgins, V. Ratziu   +28 more
semanticscholar   +1 more source

Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression

Nature Communications, 2022
Spermidine is a natural polyamine that has health benefits and extends life span in several species. Deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH) are key enzymes that utilize spermidine to catalyze the post-translational ...
Jin Zhou, J. Pang, Madhulika Tripathi, J. Ho, A. Widjaja, Shamini G Shekeran, S. Cook, A. Suzuki, A. Diehl, E. Petretto, B. Singh, P. Yen   +11 more
semanticscholar   +1 more source

Non-alcoholic steatohepatitis

European Journal of Gastroenterology & Hepatology, 2004
Non-alcoholic steatohepatitis (NASH) is an underdiagnosed liver disease characterized by steatosis, necroinflammation and fibrosis. This disease may eventually develop into cirrhosis and hepatocellular carcinoma. NASH is highly prevalent among obese individuals and among patients with diabetes mellitus type 2.
R, Vecchione, R, Giannatiempo, F, Fiorentino, L, Terracciano   +3 more
openaire   +5 more sources

Diagnosis of Non-alcoholic fatty liver disease

Journal of Pathology of Nepal, 2016
Non Alcoholic Fatty Liver Disease is the deposition of fat in liver in absence of excessive of alcohol consumption. Non Alcoholic Fatty Liver Disease ranges from simple steatosis to Nonalcoholic steatohepatitis and cirrhosis.
Geetika K.C.
doaj   +1 more source

Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression [PDF]

, 2018
The complete mechanism accounting for the progression from simple steatosis to steatohepatitis in nonalcoholic fatty liver disease (NAFLD) has not been elucidated.
Avolio, Carlo, Bellanti, Francesco, Blonda, Maria, di Bello, Giorgia, Facciorusso, Antonio, Iannelli, Giuseppina, Iuliano, Luigi, Poli, Giuseppe, Serviddio, Gaetano, Tamborra, Rosanna, Vendemiale, Gianluigi, Villani, Rosanna   +11 more
core   +2 more sources